Novel honeycomb gallo-silicate microspheres for rapid hemostasis of oral and maxillofacial wounds

高度血管化的口腔和颌面部出血不符合 通过放置止血带进行控制，通常需要使用局部止血剂(THAs)。 TAS通常用于控制严重出血，这在军事和民用中都是如此。 院前护理。在接受手术的患者中，控制止血的必要性甚至更大。 抗血栓治疗或患有出血性疾病。与此同时，口腔创伤和 拔牙部位暴露在唾液中丰富的微生物群中，这可能会导致急性或 慢性感染延迟愈合，并因抗生素耐药性的增加而复杂化 物种。这也是抗菌药物，可以防止这些并发症。我们的实验室 最近发现了一类新的高比表面积蜂窝状硅酸盐微球骨架 (SMF)能迅速止血的吸收剂。在这一发现的基础上，我们的长期目标是 利用蜂窝SMFS开发快速、局部止血和抗菌药物 与镓交换，将进一步增强止血效果，并确保抗菌 活动。外源提供的镓(以GA3+的形式)对人的抑菌效果 细菌细胞依靠其取代Fe3+的能力，从而扰乱细菌的新陈代谢。 同时，根据文献，我们假设已报道的离子止血作用 镓依靠其絮凝纤维蛋白的能力。我们多学科团队在硅酸盐领域的专业知识 将利用化学、材料化学、血液学和微生物学来开发 镓交换SMFS(Ga-SMFS)。该项目将以合成和 SMFS(AIM 1)的特性，包括其止血效果和作用机制 通过它们来促进止血。高硅酸盐微球骨架(Ga-SMFS)将是 由离子交换产生(目标2)。物理性质、镓释放特性、生物相容性 和止血效果的特征，以及镓离子增强的机制 将对止血进行调查。最后，将针对一组 相关细菌。直接释放物是一种具有双重止血功能的新型抗菌剂THAs 行动，触发快速止血和预防感染，可以很好地承受应用 除口腔和颌面部术后出血外。

Hemorrhages in the highly vascularized oral and maxillofacial region are not amenable to control by tourniquet placement and often require the use of Topical Hemostatic Agents (THAs). THAs are commonly used to control severe bleeding, this is the case in both military and civilian pre-hospital care. The need for controlling hemostasis is even greater in patients undergoing antithrombotic therapy or suffering from bleeding disorders. Meanwhile, oral wounds and extraction sites are exposed to the rich microflora present in saliva, which can induce acute or chronic infections that delay healing, and are complicated by the rise of antibiotic-resistant species. THAs that are also antimicrobial would prevent these complications. Our laboratory recently discovered a new class of high surface area, honeycomb silicate microsphere framework (SMF) absorbents that prompt rapid hemostasis. Building on this discovery, our long-term goal is to develop fast-action, topical hemostatic and antimicrobial agents using honeycomb SMFs exchanged with gallium, which will further strengthen hemostatic efficacy and ensure antimicrobial activity. The antimicrobial efficacy of exogenously supplied gallium (in the form of Ga3+) to bacterial cells relies on its ability to replace Fe3+, thereby perturbing bacterial metabolism. Concurrently, based on the literature, we hypothesize that the reported hemostatic action of ionic gallium relies on its ability to flocculate fibrin. The expertise of our multidisciplinary team in silicate chemistry, materials chemistry, hematology, and microbiology will be leveraged to develop gallium-exchanged SMFs (Ga-SMFs). The project will initiate with the synthesis and characterization of SMFs (Aim 1), including their hemostatic efficacy as well as the mechanisms by which they promote hemostasis. Gallo-silicate microsphere frameworks (Ga-SMFs) will be produced by ion-exchange (Aim 2). Physical properties, gallium release profiles, biocompatibility and hemostatic efficacy will be characterized, and mechanisms by which gallium ion enhances hemostasis will be investigated. Finally, the antimicrobial efficacy will be tested against a panel of relevant bacteria. Direct deliverables are a new class of antimicrobial THAs with dual hemostatic action, triggering rapid hemostasis and preventing infections, that could bear applications well beyond oral and maxillofacial post-surgical hemorrhages.